Man­u­fac­tur­ing roundup: Bio­con ac­quires New Jer­sey man­u­fac­tur­ing site for $7M+; Ghana­ian man­u­fac­tur­er to fill-fin­ish cholera vac­cine

Bio­con Gener­ics, a sub­sidiary of In­dia-based man­u­fac­tur­er Bio­con, has ac­quired an oral med­i­cine pro­duc­tion fa­cil­i­ty in Cran­bury, NJ, from gener­ic man­u­fac­tur­er Ey­wa Phar­ma for $7.7 mil­lion.

The deal closed on Sept. 1, and staff at the site will trans­fer to Bio­con Gener­ics, ac­cord­ing to a press re­lease. The site can pro­duce two bil­lion tablets per year, but no de­tails on what ex­act­ly will be made were dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER